GSK, Jefferies
Quarterly sales of GSK's RSV vaccine dropped more than 70%, following narrower recommendations for who should get the shot.
GSK on Wednesday said its vaccine sales would fall this year, after a weaker-than-expected performance for its respiratory ...
The print ads featured a prominent display of a person’s back, highlighting where shingles rashes typically emerge.
GSK managed to beat analysts’ revenue predictions ... driven once again by its shingles vaccine Shingrix and HIV therapies sold under the ViiV Healthcare joint venture. Shingrix grew 19% to ...
The British pharma’s experience during the third quarter mirrored that of rival Pfizer, which also reported lower sales of ...
To pile on, GSK’s flagship shingles vaccine Shingrix also saw a 10% sales reduction in the third quarter to 739 million pounds ($956 million). The number missed analysts’ projections by 13%.
GSK reports Q3 sales of $10.42 billion, missing estimates due to an 18% drop in vaccine revenue, while specialty medicines ...
GSK's major growth drivers, Shingrix and Arexvy, along with recent legal progress, make its current undervaluation unjustified, leading to a "Strong Buy" rating. The company’s diversified ...
14d
GSK PLC (GSK) reports robust year-to-date sales growth, driven by Specialty Medicines, while navigating vaccine sales ...
GSK's shares are falling 4% in premarket trading Wednesday after the British pharma giant posted lower-than-estimated ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback